Blair William & Co. IL Has $541,000 Position in Bausch Health Cos Inc. $BHC

Blair William & Co. IL cut its stake in Bausch Health Cos Inc. (NYSE:BHC) by 4.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 81,247 shares of the company’s stock after selling 3,500 shares during the period. Blair William & Co. IL’s holdings in Bausch Health Cos were worth $541,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Nomura Holdings Inc. raised its holdings in Bausch Health Cos by 106.2% in the 1st quarter. Nomura Holdings Inc. now owns 23,395,000 shares of the company’s stock valued at $151,366,000 after acquiring an additional 12,050,000 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Bausch Health Cos by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 11,746,480 shares of the company’s stock worth $76,152,000 after buying an additional 61,621 shares in the last quarter. Private Management Group Inc. raised its holdings in shares of Bausch Health Cos by 13.8% during the 1st quarter. Private Management Group Inc. now owns 1,439,426 shares of the company’s stock worth $9,313,000 after buying an additional 174,176 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Bausch Health Cos by 4.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,341,999 shares of the company’s stock worth $8,700,000 after buying an additional 57,963 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Bausch Health Cos by 97.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company’s stock worth $6,136,000 after buying an additional 467,270 shares in the last quarter. 78.65% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BHC has been the subject of a number of research analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Bausch Health Cos in a report on Wednesday, October 8th. Wall Street Zen cut Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 11th. Three equities research analysts have rated the stock with a Hold rating, According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $9.00.

Bausch Health Cos Trading Up 0.7%

NYSE BHC opened at $6.06 on Friday. The firm has a market capitalization of $2.25 billion, a PE ratio of 23.29 and a beta of 0.43. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 141.90. The business’s 50-day moving average price is $6.94 and its two-hundred day moving average price is $6.01. Bausch Health Cos Inc. has a 12 month low of $4.25 and a 12 month high of $9.85.

Bausch Health Cos (NYSE:BHC) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.97 by ($0.07). The business had revenue of $2.57 billion during the quarter, compared to analyst estimates of $2.47 billion. Bausch Health Cos had a net margin of 0.99% and a negative return on equity of 852.36%. Bausch Health Cos has set its FY 2025 guidance at EPS. On average, analysts expect that Bausch Health Cos Inc. will post 4.41 EPS for the current year.

Insider Activity

In other Bausch Health Cos news, Director John Paulson acquired 34,721,118 shares of the company’s stock in a transaction dated Thursday, August 14th. The shares were bought at an average cost of $9.00 per share, with a total value of $312,490,062.00. Following the purchase, the director directly owned 70,755,869 shares of the company’s stock, valued at $636,802,821. This trade represents a 96.35% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last 90 days, insiders bought 37,964,167 shares of company stock valued at $333,757,793. 19.97% of the stock is owned by insiders.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.